Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $90→$95 | ― | 11.10% | Downgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $260→$225 | ― | 6.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $30 | ― | 14.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $15 | ― | 14.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $31 | ― | 12.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $200 | ― | 11.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $38 | ― | 7.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $46→$50 | ― | 1.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $44→$41 | ― | 23.00% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $200→$215 | ― | 6.70% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $3 | ― | 4.50% | Reiterated | ||||
 | Biogen | BUY $294→$300 | ― | -0.90% | Reiterated | Biogen price target raised to $300 from $294 at Baird | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $190→$200 | ― | 8.70% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $115 | ― | 3.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $70 | ― | 3.40% | Assigned | ||||
| Enliven Therapeutics | BUY $32→$40 | ― | -7.80% | Reiterated | Enliven price target raised to $40 from $32 at Baird | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $26→$29 | ― | 5.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $6→$7 | ― | 13.80% | Reiterated | ||||
| TreeHouse Foods | HOLD | ― | -4.80% | Downgraded | TreeHouse downgraded to Equal Weight from Overweight at Consumer Edge | |||
| Ascendis Pharma | BUY $181 | ― | -21.00% | Initiated | Positive Outlook and Strategic Growth Catalysts Reinforce Buy Rating for Ascendis Pharma | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $70→$76 | ― | 8.80% | Downgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $153 | ― | 13.60% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $135→$112 | ― | 9.40% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $142 | ― | 15.50% | Assigned | ||||
 | BioNano Genomics | HOLD | ― | -4.10% | Downgraded | Bionano Genomics downgraded to Neutral from Buy at Ladenburg | |||
 | Weave Communications | BUY $17 | ― | -3.80% | Assigned | Piper Sandler Sticks to Their Buy Rating for Weave Communications (WEAV) | |||
| Snowflake | BUY $165 | ― | -3.80% | Reiterated | New Buy Rating for Snowflake (SNOW), the Technology Giant | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $140 | ― | 6.00% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $14 | ― | 5.50% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $20 | ― | 5.50% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $118 | ― | 5.50% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $13→$16 | ― | 10.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $313 | ― | 11.60% | Assigned | ||||
 | GE Healthcare Technologies Inc | BUY $97 | ― | -5.10% | Assigned | Piper Sandler Reaffirms Their Buy Rating on GE Healthcare Technologies Inc (GEHC) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $52 | ― | 11.40% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $30 | ― | 7.90% | Assigned | ||||
 | Poseida Therapeutics | BUY $10 | ― | -12.60% | Reiterated | Poseida Therapeutics (PSTX) Receives a Buy from Piper Sandler | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $38 | ― | 13.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $101 | ― | 13.60% | Reiterated | ||||
| American Well | HOLD $10 | ― | -3.20% | Reiterated | Piper Sandler Reaffirms Their Hold Rating on American Well (AMWL) | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $6 | ― | 13.60% | Reiterated | ||||
| Omega Therapeutics | BUY $4 | ― | -12.60% | Assigned | Piper Sandler Remains a Buy on Omega Therapeutics (OMGA) | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $4 | ― | 4.80% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $12 | ― | 13.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $7.5→$5.5 | ― | 4.50% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $4.5→$5 | ― | 2.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $3→$2 | ― | 1.30% | Downgraded | ||||
 | Compass Therapeutics | HOLD $4 | ― | -5.20% | Downgraded | Hold Rating Issued for Compass Therapeutics Amid CTX-009 Uncertainty and Strategic Concerns | |||
| Enphase Energy | HOLD $93→$74 | ― | -3.60% | Reiterated | Enphase Energy price target lowered to $74 from $93 at Morgan Stanley | |||
Oliver McCammonLifeSci Capital Not Ranked | Celcuity | BUY $27 | ― | ― | Reiterated | Celcuity's Promising Prospects: Clinical Advancements and Market Opportunities Drive Buy Rating |
Rows:
